Although the effect of inhibiting IL-13 for IBD patients remains controversial, a recent study that found a high frequency of autoantibodies against integrin αvβ6 in UC patients suggests the possible contribution of type 2 immune responses in the pathogenesis in IBD (119). This evidence concerns the gene IL13 and inflammatory bowel disease.